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OBJECTIVE: The pathophysiology of coronary slow flow has not been clearly defined, although multiple
abnormalities including arteritis, endothelial dysfunction, and atherothrombosis, have been reported. It is
known that eosinophils play an important role in inflammation, endothelial dysfunction, and thrombosis. We
aimed to compare the eosinophil counts of coronary slow flow patients versus healthy controls.
METHODS: This study included 50 coronary slow flow patients (19 males, mean age 65.6¡13.7 years) and 30
healthy controls (10 males, mean age 57.86¡11.6 years). These participants were evaluated using concurrent
routine biochemical tests as well as neutrophil, lymphocyte, and eosinophil counts and mean platelet volume
(MPV), which were obtained from the whole blood count. These parameters were compared between groups.
RESULTS: The baseline characteristics of the study groups were comparable. The coronary slow flow patients
had a higher mean platelet volume and eosinophil count than the control group (8.38¡0.86 vs 6.28¡1.6 fL and
0.31¡0.42 vs 0.09¡0.05; p,0.001 and 0.008, respectively).
CONCLUSION: Our study demonstrated a relationship between eosinophil count and MPV in patients with coro-
nary slow flow.
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& INTRODUCTION
Coronary slow flow (CSF) is characterized by the delayed
opacification of coronary arteries in the absence of obstruc-
tive coronary artery disease (CAD) on coronary angiogra-
phy (1).
Several mechanisms have been proposed for the etiology
of CSF, including microvascular and endothelial dysfunc-
tion, small vessel disease, diffuse atherosclerosis, and inflam-
mation. However, its etiopathogenesis remains unclear (2,3).
Coronary atherosclerosis, disturbed microvascularization
functions, and endothelial dysfunction have been reported
to be closely related to CSF (4,5). A significant relationship
has also been reported between inflammatory markers and
coronary flow rate (6,7).
Eosinophils are known to play an important role in
endothelial dysfunction, inflammation, and thrombosis
(8,9). Additionally, vascular anomalies, such as aneurysms,
have been noted in patients with hypereosinophilic syn-
dromes (10,11).
The powerful vasoactive and procoagulant effects of
eosinophils led us to hypothesize that a correlation exists
between eosinophil concentrations and CSF. To our knowl-
edge, to date, no studies have examined the relationship
between blood eosinophil concentration and CSF. In our
study, we compared eosinophil counts between CSF
patients and healthy controls.
& MATERIALS AND METHODS
Patients
The study group included 50 patients (19 males, mean age
65.6+/-13.7 years) with isolated CSF without any stenotic
lesions under visual assessment. The control group con-
sisted of 30 age- and gender-matched subjects (10 males,
mean age 49.16+/-9.2 years) with normal coronary angio-
grams.
In both groups, the indication for coronary angiography
was the presence of typical angina or positive or equivocal
results for myocardial ischemia on noninvasive screening
tests.
Both groups underwent medical history reviews and
physical, blood biochemistry, and transthoracic echocardio-
graphic examinations to exclude systemic diseases. The
following exclusion criteria were applied: obstructive CAD
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(coronary stenotic lesions.20%), chronic renal failure,
chronic liver disorders, chronic lung disease, moderate or
severe valvular disease, hypertension, diabetes mellitus,
congenital heart disease; left ventricular systolic dysfunction
on echocardiography (EF,50%), anemia, pregnancy, obstruc-
tive sleep apnea, hematological disorders, known malig-
nancy, thyroid dysfunction, hypercholesterolemia, electro-
lyte imbalance, and a drug history that included anti-gout,
anti-inflammatory (steroid or nonsteroidal), antiaggregant,
anticoagulant, or antihistamine agents or any medication
that could potentially interfere with the measurement of
eosinophil counts. Patients with recent histories of acute
infection and/or a high body temperature (.38 C˚) or an
inflammatory or allergic disease were also excluded from
the study.
Patients with systolic blood pressure $140 mmHg and/
or diastolic blood pressure $90 mmHg and those taking
antihypertensive drugs were considered to be hyperten-
sive. Diabetes was defined as a fasting blood glucose level
.126 mg/dl or current use of a diet or medication to lower
blood glucose. Current cigarette smoking was defined as
.10 cigarettes/day at the time of diagnosis.
Coronary angiography
Coronary angiograms were performed with a femoral
approach using the Judkins technique, without the use of
nitroglycerin, adenosine, or calcium channel blockers. All
patients in the study population underwent elective
coronary artery angiography using a Siemens Axiom Artis
DFC (Siemens AG, Forchheim Germany) following appro-
priate patient preparation. Coronary angiograms were
judged by smooth appearance, luminal wall irregularities,
epicardial local or diffuse caliber reduction, and stenosis.
Coronary arteries were observed in at least four views of the
left coronary system using 6-French left coronary catheters,
and two views of the right coronary artery were obtained
using 6-French right coronary catheters with a 15 fps rate in
the same cardiac catheterization laboratory. Coronary blood
flow was measured quantitatively using the thrombolysis in
myocardial infarction frame count (TFC). The initial frame
count is defined as the frame in which concentrated dye
occupies the full width of the proximal coronary artery
lumen, touching both borders of the lumen, and exhibiting
forward motion down the artery. The final frame is
designated when the leading edge of the contrast column
initially arrives at the distal end. The distal end was defined
as the distal bifurcation for the left anterior descending
(LAD) artery, the distal bifurcation of the segment with the
longest total distance for the circumflex artery (CX), and the
first branch of the posterolateral artery for the right
coronary artery (RCA). The LAD coronary artery is usually
longer than the other major coronary arteries; the TFC for
this vessel is often higher. To obtain the corrected TFC for
the LAD coronary artery, the TFC was divided by 1.7. The
mean TFC for each patient and control subject was
calculated by adding the TFC for the LAD, CX, and RCA
and then dividing three by the obtained value. Because of
the different durations required for normal visualization of
the coronary arteries, the corrected cutoff values were
36.28¡2.6 frames for the LAD, 22.28¡4.1 frames for the CX,
and 20.48¡3 frames for the RCA, as previously reported in
the literature (12). All participants with a TFC greater than
two standard deviations of the previously published range
for a particular vessel were considered to have CSF. Any
values obtained above these thresholds in one of the three
coronary arteries (not all three) were considered to indicate
CSF in our study. Coronary angiograms and TFC were
analyzed by two experienced interventional cardiologists
who were blinded to the clinical status and laboratory
measurements of the subjects.
Laboratory tests
Biochemical parameters were analyzed spectrophotome-
trically using an Architect C16000 (Abbott, USA) Auto-
Analyzer following an enzymatic-colorimetric assay.
For the whole blood count (i.e., eosinophil count,
hematocrit, hemoglobin, MCV, MPV, leukocytes, neutro-
phils, lymphocytes, and platelets), blood samples were
collected into tubes containing ethylenediaminetetraacetic
acid (EDTA) and analyzed within 2 hours after blood
sampling with a CELL-DYN 3700 (Abbott. USA) device
using the impedance and optic scatter method.
Statistical analysis
The SPSS 16.0 statistical program (SPSS Inc., Chicago, IL,
USA) was used for the statistical analyses. All values are
given as the mean¡standard deviation. The mean values of
continuous variables were compared between groups using
Student’s t test or the Mann–Whitney U test, based on
whether the values were normally distributed, as indicated
by the Kolmogorov–Smirnov test. To define the relationship
between CSF and possible confounding factors, logistic
regression analysis was used and p,0.05 was considered to
be significant.
& RESULTS
The basic clinical and demographic characteristics were
compared, and there were no statistically significant
between-group differences in terms of age, gender distribu-
tion, body mass index, smoking status, or biochemical
parameters (Table 1).
The TFC for all epicardial coronary arteries and the mean
TFC were significantly greater in the CSF group than in the
Table 1 - A comparison of the basic clinical and
biochemical features of the patients and controls.
Patients
(n = 50)
Controls
(n = 30) p value
Age (years) 65.6¡13.7 57.86¡11.6 NS
Sex (n, %) males 19 (38%) 10 (33%) NS
Body mass index
(BMI) (kg/m2)
29.9¡6.3 28.5¡4.6 NS
Smoking 10 (20%) 6 (20%) NS
Fasting glucose
(mg/dl)
92¡7 97.6¡8.5 NS
Creatinine (mg/dl) 0.78¡0.3 0.72¡0.2 NS
Total cholesterol
(mg/dl)
202¡55 181¡36 NS
Triglycerides
(mg/dl)
166.5¡52 151.9¡41 NS
TSH (mIU/mL) 1.8¡0.5 1.6¡0.4 NS
cLAD TFC 37.2¡6.9 18.1¡4.6 ,0.001
Cx TFC 31.5¡6.1 19.3¡3.6 ,0.001
RCA TFC 27.6¡5.1 18.5¡3.3 ,0.001
Mean TFC 31.1¡3.3 18.6¡2.3 ,0.001
TSH: thyroid-stimulating hormone; NS: nonsignificant; LAD: left anterior
descending artery; cLAD: corrected TIMI frame count for LAD; TFC: TIMI
frame count, Cx: circumflex artery, RCA: right coronary artery.
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control group. The mean TFC of all CSF patients was greater
than that of the control group (Table 1).
Regarding the blood count parameters, in the CSF patient
group, the blood eosinophil count and MPV were signifi-
cantly higher compared with those in the control group.
There was no statistically significant difference between the
two groups with regard to the leukocyte count, platelet
count, hemoglobin, or hematocrit level (Table 2).
Using logistic regression analysis, eosinophil count andMPV
were found to be significantly associated with CSF (Table 3).
& DISCUSSION
The main finding of this study was that the eosinophil
count and MPV increased in the CSF patients compared
with the healthy controls. To the best of our knowledge, our
study is the first report to focus on the relationship between
the eosinophil count and CSF.
In the present study, we identified an independent associa-
tion between the eosinophil count and CSF. We demon-
strated that CSF patients had an increased eosinophil count
compared with the controls, who exhibited normal coronary
arteries.
The pathophysiology of CSF has not been clearly
identified, although multiple abnormalities, including
inflammation, oxidative stress, endothelial dysfunction,
vasculitis, platelet function disorder, and atherothrombosis,
have been reported (13-15).
Previous studies have demonstrated that the C-reactive
protein (CRP) and interleukin 6 levels and the neutrophil
lymphocyte ratio (NLR) are greater in CSF patients than
in healthy controls. The CRP and NLR increases may
suggest that these markers can be used in clinical practice
to assess the inflammatory statuses of CSF patients
(1,16,17).
Eosinophils induce the activation of the coagulation
system and platelets, as well as inflammation, endothelial
dysfunction, and aneurysm. Additionally, eosinophils play
a role in vascular injury (10).
To our knowledge, no studies in the literature have
examined the association between CSF and eosinophil count.
In our study, we found significant MPV differences
between the CSF patients and controls. Our findings align
with those of previous studies (18,19). Additionally, when
the two groups were compared in our study, the eosinophil
counts of the CSF patients were significantly greater than
those of the controls.
Eosinophils contain several granule-associated molecules
that play a role in the occurrence of thrombosis and vascular
injury. Eosinophils can increase the risk of thrombosis
through leukocyte and platelet stimulation and the release
of tissue factor (20,21). These effects contribute to procoa-
gulation by preventing the activation of thrombin and by
inducing fibrin formation. Eosinophils store and release
tissue factor and other cationic proteins. Major basic protein
and eosinophilic cationic protein activate platelets and
promote thrombus formation by inhibiting thrombomodu-
lin in hypereosinophilic syndromes and allergic diseases.
Reportedly, activated eosinophils and secreted eosinophil
granule proteins are most evident within necrotic and later-
stage thrombotic lesions and are found primarily within the
areas of acute tissue damage in the endocardium and in the
walls of small blood vessels. These findings suggest that
eosinophil granule proteins are involved in vascular injury
and that eosinophils may affect the cardiovascular system
by inducing inflammatory cell infiltration (22,23).
Recent studies have reported that eosinophils are asso-
ciated with arterial tortuosity, dilatation, thrombosis, car-
diac syndrome X, and non-dipper hypertension (24,25).
Major basic protein, eosinophilic cationic protein, and
eosinophil-derived neurotoxin are the primary mediators of
eosinophil-associated toxicity to human tissue and may
induce eosinophilic myocarditis, pneumonitis, dermatitis,
neuropathy, and vasculitis (10).
The powerful vasoactive, inflammatory, and procoagu-
lant effects of eosinophils led us to hypothesize that a
correlation exists between the eosinophil concentration and
CSF. In the literature, no studies have examined the
association between CSF and eosinophils. Therefore, our
study is of particular importance, as we investigated the
association between eosinophil concentration and CSF in
our patients.
The most important restriction of our study is the limited
number of patients. Furthermore, the angiographic diag-
nosis of normal coronary arteries was based on axial
contrast angiography of the vessel lumen, which under-
estimates the presence of atherosclerotic plaques. Additional
studies are required to determine the relationship between
eosinophil count and CSF.
The eosinophil count is increased in CSF patients, and it is
significantly and independently associated with CSF. Our
results may contribute to the understanding of the etio-
pathogenesis of CSF and the pathophysiological mechan-
isms underlying the increased prevalence of cardiovascular
morbidity and increased mortality risk in these patients. The
increased concentration of eosinophils might be associated
with the vascular destruction, endothelial dysfunction, and
thrombosis observed in CSF patients.
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Table 2 - A comparison of the whole blood count features
of the patients and controls.
Patients
(n = 50)
Controls
(n = 30) p value
Leukocyte (10‘3/mI) 7.83¡5.5 7.72¡5.4 NS
Eosinophil count (10‘3/mI) 0.31¡0.42 0.09¡0.05 0.008
Mean platelet volume (MPV) (fL) 8.38 ¡0.86 6.28¡1.6 ,0.001
Hemoglobin (g/dL) 13.9 ¡1.71 13.59¡1.59 NS
Hematocrit (%) 41.3¡4.2 40.7¡3.49 NS
Platelet (10ˆ3/mI) 266¡82 236¡73 NS
NS: nonsignificant.
Table 3 - Multiple logistic regression analysis of CSF.
Odds Ratio
95% Confidence
Interval p value
Eosinophils 1.02 1.006-1.018 0.076
Mean platelet volume 4.2 2.20-8.42 ,0.001
Leukocytes 0.95 0.91-1.0 0.130
Hemoglobin 1.007 0.07-1.20 0.734
Platelets 1.01 1.005-1.017 0.570
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